{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:24:00Z","timestamp":1789421040793,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jconrel.2024.07.058","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T21:02:08Z","timestamp":1722891728000},"page":"879-889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Intelligent micelles for on-demand drug delivery targeting extracellular matrix of pancreatic cancer"],"prefix":"10.1016","volume":"373","author":[{"given":"Chufeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jconrel.2024.07.058_bb0005","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.jconrel.2024.07.058_bb0010","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1053\/j.gastro.2020.10.007","article-title":"Worldwide burden of, risk factors for, and trends in pancreatic cancer","volume":"160","author":"Huang","year":"2021","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jconrel.2024.07.058_bb0015","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","article-title":"Therapeutic developments in pancreatic cancer: current and future perspectives","volume":"15","author":"Neoptolemos","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.jconrel.2024.07.058_bb0020","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/13543784.2019.1557145","article-title":"Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)","volume":"28","author":"Chandana","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jconrel.2024.07.058_bb0025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jconrel.2023.12.053","article-title":"Recent advances in drug delivery and targeting for the treatment of pancreatic cancer","volume":"366","author":"Pramanik","year":"2024","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.jconrel.2024.07.058_bb0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41568-020-00329-7","article-title":"The matrix in cancer","volume":"21","author":"Cox","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2024.07.058_bb0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther."},{"issue":"3 Pt 2","key":"10.1016\/j.jconrel.2024.07.058_bb0040","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.lpm.2019.02.025","article-title":"Chemotherapy for pancreatic cancer","volume":"48","author":"Springfeld","year":"2019","journal-title":"Presse Med."},{"issue":"4","key":"10.1016\/j.jconrel.2024.07.058_bb0045","doi-asserted-by":"crossref","first-page":"688","DOI":"10.20892\/j.issn.2095-3941.2019.0252","article-title":"The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview","volume":"16","author":"Quinonero","year":"2019","journal-title":"Cancer Biol. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2024.07.058_bb0050","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1039\/D3BM01118F","article-title":"Stromal and tumor immune microenvironment reprogramming through multifunctional cisplatin-based liposomes boosts the efficacy of anti-PD-1 immunotherapy in pancreatic cancer","volume":"12","author":"Yu","year":"2023","journal-title":"Biomater. Sci."},{"issue":"9","key":"10.1016\/j.jconrel.2024.07.058_bb0055","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.jconrel.2024.07.058_bb0060","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.jconrel.2024.07.058_bb0065","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1158\/1078-0432.CCR-15-2010","article-title":"Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer","volume":"22","author":"Hingorani","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.jconrel.2024.07.058_bb0070","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.18.01295","article-title":"Phase IB\/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313","volume":"37","author":"Ramanathan","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.jconrel.2024.07.058_bb0075","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.3748\/wjg.v27.i18.2105","article-title":"Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects","volume":"27","author":"Polani","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2024.07.058_bb0080","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jconrel.2022.02.020","article-title":"Tumor-permeable smart liposomes by modulating the tumor microenvironment to improve the chemotherapy","volume":"344","author":"Widjaya","year":"2022","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.jconrel.2024.07.058_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/biom12101450","article-title":"STAT3 inhibitors: a novel insight for anticancer therapy of pancreatic cancer","volume":"12","author":"Li","year":"2022","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.jconrel.2024.07.058_bb0090","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/s41388-020-01626-z","article-title":"Targeting STAT3 by a small molecule suppresses pancreatic cancer progression","volume":"40","author":"Chen","year":"2021","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.jconrel.2024.07.058_bb0095","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2022.07.076","article-title":"Combined MEK and STAT3 inhibition uncovers stromal plasticity by enriching for cancer-associated fibroblasts with mesenchymal stem cell-like features to overcome immunotherapy resistance in pancreatic cancer","volume":"163","author":"Datta","year":"2022","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jconrel.2024.07.058_bb0100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in cancer immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2024.07.058_bb0105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jconrel.2021.05.010","article-title":"PEG-polyaminoacid based micelles for controlled release of doxorubicin: Rational design, safety and efficacy study","volume":"335","author":"Brunato","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.07.058_bb0110","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jconrel.2022.07.009","article-title":"Microenvironment-tailored micelles restrain carcinoma-astrocyte crosstalk for brain metastasis","volume":"349","author":"Zhao","year":"2022","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.jconrel.2024.07.058_bb0115","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1021\/acs.molpharmaceut.3c00116","article-title":"Recent advances in perfluorocarbon-based delivery systems for cancer theranostics","volume":"20","author":"Yang","year":"2023","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.jconrel.2024.07.058_bb0120","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1039\/C7BM01051F","article-title":"Acid- and reduction-sensitive micelles for improving the drug delivery efficacy for pancreatic cancer therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.jconrel.2024.07.058_bb0125","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jconrel.2022.05.056","article-title":"Preparation and application of pH-responsive drug delivery systems","volume":"348","author":"Ding","year":"2022","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.jconrel.2024.07.058_bb0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1208\/s12249-022-02316-7","article-title":"A hypoxia-sensitive drug delivery system constructed by nitroimidazole and its application in the treatment of hepatocellular carcinoma","volume":"23","author":"Meng","year":"2022","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.jconrel.2024.07.058_bb0135","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1080\/10717544.2021.1992039","article-title":"GLUT1 targeting and hypoxia-activating polymer-drug conjugate-based micelle for tumor chemo-thermal therapy","volume":"28","author":"Ma","year":"2021","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2024.07.058_bb0140","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.actbio.2023.05.047","article-title":"Gradient tumor microenvironment-promoted penetrating micelles for hypoxia relief and immunosuppression reversion in pancreatic cancer treatment","volume":"167","author":"Luo","year":"2023","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.jconrel.2024.07.058_bb0145","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.apsb.2022.05.027","article-title":"A neutrophil-biomimic platform for eradicating metastatic breast cancer stem-like cells by redox microenvironment modulation and hypoxia-triggered differentiation therapy","volume":"13","author":"Chu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2024.07.058_bb0150","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2017.06.003","article-title":"Targeting STAT3 with silibinin to improve cancer therapeutics","volume":"58","author":"Bosch-Barrera","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"11","key":"10.1016\/j.jconrel.2024.07.058_bb0155","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1080\/15563650.2022.2128815","article-title":"Silibinin: a toxicologist\u2019s herbal medicine?","volume":"60","author":"Horowitz","year":"2022","journal-title":"Clin. Toxicol. (Phila)."},{"issue":"6","key":"10.1016\/j.jconrel.2024.07.058_bb0160","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ctrv.2015.04.008","article-title":"Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy","volume":"41","author":"Bosch-Barrera","year":"2015","journal-title":"Cancer Treat. Rev."},{"issue":"6","key":"10.1016\/j.jconrel.2024.07.058_bb0165","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.3892\/or.2017.5588","article-title":"Silibinin downregulates MMP2 expression via Jak2\/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells","volume":"37","author":"Byun","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jconrel.2024.07.058_bb0170","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijpharm.2019.02.032","article-title":"CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment","volume":"561","author":"Tirella","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.jconrel.2024.07.058_bb0175","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3109\/01902148.2014.905656","article-title":"Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44","volume":"40","author":"Quan","year":"2014","journal-title":"Exp. Lung Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924005169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924005169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T20:56:34Z","timestamp":1725742594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924005169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":35,"alternative-id":["S0168365924005169"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.07.058","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intelligent micelles for on-demand drug delivery targeting extracellular matrix of pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.07.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}